MiR-126 Inhibits Cell Growth, Invasion, and Migration of Osteosarcoma Cells by Downregulating ADAM-9

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 Sep 13

PMID 25213697

Citations 17

Authors

Liangdong Jiang

Aiyong He

Qing Zhang

Cheng Tao

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) has become one of the most common primary malignant tumors in the children and adolescents with a poor prognosis mainly due to high metastasis. A disintegrin and metalloprotease 9 (ADAM-9) plays a role in tumorigenesis, invasion, and metastasis in several tumors. miR-126 has been reported to be downregulated in OS tumor. However, the involvement of ADAM-9 in the pathology of OS and the relationship between miR-126 and ADAM-9 in OS cells remain unclear. In this study, using quantitative reverse-transcribed PCR (qRT-PCR) analysis on 37 pairs of OS tumors and matched adjacent normal bone tissues, we found that ADAM-9 is significantly upregulated, while miR-126 is downregulated in human OS tumors. Association analysis revealed that upregulation of ADAM-9 and downregulation of miR-126 are significantly involved in advanced clinical stage development and distant metastasis. Luciferase reporter assay revealed that miR-126 could directly target ADAM-9 3' untranslated region (UTR) and inhibit its expression in U2OS and MG-63 cells. Functional experiments revealed that downregulating ADAM-9 by miR-126 inhibited cellular growth, invasion, and migration in U2OS and MG-63 cells. In rescue experiments, restored ADAM-9 expression attenuated miR-126-mediated suppression, while knockdown of ADAM-9 by small interfering RNA (siRNA) represented similar results with miR-126-mediated tumor suppression in U2OS cells. Taken together, our data indicated that miR-126 inhibits cell growth, invasion, and migration of OS cells by downregulating ADAM-9.

Citing Articles

Circ_0061140 Potentiates Clear Cell Renal Cell Carcinoma Progression Via the MicroRNA-126-5p/ADAM9 Axis.

Jia G, Lv D, Ni S Mol Biotechnol. 2023; 66(12):3688-3699.

PMID: 38062234 DOI: 10.1007/s12033-023-00977-8.

Role of MicroRNAs in Human Osteosarcoma: Future Perspectives.

Llobat L, Gourbault O Biomedicines. 2021; 9(5).

PMID: 33922820 PMC: 8146779. DOI: 10.3390/biomedicines9050463.

circPVT1 promotes osteosarcoma glycolysis and metastasis by sponging miR-423-5p to activate Wnt5a/Ror2 signaling.

Wan J, Liu Y, Long F, Tian J, Zhang C Cancer Sci. 2020; 112(5):1707-1722.

PMID: 33369809 PMC: 8088910. DOI: 10.1111/cas.14787.

miRNA signatures in childhood sarcomas and their clinical implications.

Viera G, Salomao K, de Sousa G, Baroni M, Delsin L, Pezuk J Clin Transl Oncol. 2019; 21(12):1583-1623.

PMID: 30949930 DOI: 10.1007/s12094-019-02104-z.

Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.

Ouyang Z, Wang S, Zeng M, Li Z, Zhang Q, Wang W Cell Commun Signal. 2019; 17(1):17.

PMID: 30808351 PMC: 6390580. DOI: 10.1186/s12964-019-0327-5.

References

Edwards D, Handsley M, Pennington C . The ADAM metalloproteinases. Mol Aspects Med. 2008; 29(5):258-89. PMC: 7112278. DOI: 10.1016/j.mam.2008.08.001. View

Sung S, Kubo H, Shigemura K, Arnold R, Logani S, Wang R . Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res. 2006; 66(19):9519-26. DOI: 10.1158/0008-5472.CAN-05-4375. View

Wu X, Zhong D, Gao Q, Zhai W, Ding Z, Wu J . MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression. Int J Med Sci. 2013; 10(6):676-82. PMC: 3619116. DOI: 10.7150/ijms.5528. View

Govoni K, Amaar Y, Kramer A, Winter E, Baylink D, Mohan S . Regulation of insulin-like growth factor binding protein-5, four and a half lim-2, and a disintegrin and metalloprotease-9 expression in osteoblasts. Growth Horm IGF Res. 2005; 16(1):49-56. PMC: 2904509. DOI: 10.1016/j.ghir.2005.10.001. View

Hamada S, Satoh K, Fujibuchi W, Hirota M, Kanno A, Unno J . MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res. 2011; 10(1):3-10. DOI: 10.1158/1541-7786.MCR-11-0272. View

Ebrahimi F, Gopalan V, Smith R, Lam A . miR-126 in human cancers: clinical roles and current perspectives. Exp Mol Pathol. 2013; 96(1):98-107. DOI: 10.1016/j.yexmp.2013.12.004. View

Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y . miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 2013; 15(3):284-94. PMC: 3672398. DOI: 10.1038/ncb2690. View

Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F . microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep. 2010; 24(5):1363-9. DOI: 10.3892/or_00000994. View

Zhang J, Qi J, Chen N, Fu W, Zhou B, He A . High expression of a disintegrin and metalloproteinase-9 predicts a shortened survival time in completely resected stage I non-small cell lung cancer. Oncol Lett. 2013; 5(5):1461-1466. PMC: 3678878. DOI: 10.3892/ol.2013.1209. View

10.

Mazzocca A, Coppari R, De Franco R, Cho J, Libermann T, Pinzani M . A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005; 65(11):4728-38. DOI: 10.1158/0008-5472.CAN-04-4449. View

11.

Duffy M, McKiernan E, ODonovan N, McGowan P . Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009; 15(4):1140-4. DOI: 10.1158/1078-0432.CCR-08-1585. View

12.

Xu J, Liu P, Si M, Ding X . MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1. Tumour Biol. 2013; 34(6):3871-7. DOI: 10.1007/s13277-013-0974-x. View

13.

Zhang B, Pan X, Cobb G, Anderson T . microRNAs as oncogenes and tumor suppressors. Dev Biol. 2006; 302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.028. View

14.

Alfandari D, McCusker C, Cousin H . ADAM function in embryogenesis. Semin Cell Dev Biol. 2008; 20(2):153-63. PMC: 2693894. DOI: 10.1016/j.semcdb.2008.09.006. View

15.

Mohan S, Thompson G, Amaar Y, Hathaway G, Tschesche H, Baylink D . ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry. 2002; 41(51):15394-403. DOI: 10.1021/bi026458q. View

16.

Namlos H, Meza-Zepeda L, Baroy T, Ostensen I, Kresse S, Kuijjer M . Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One. 2012; 7(10):e48086. PMC: 3485010. DOI: 10.1371/journal.pone.0048086. View

17.

Kager L, Potschger U, Bielack S . Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag. 2010; 6:279-86. PMC: 2893760. DOI: 10.2147/tcrm.s5688. View

18.

Liu Y, Zhou Y, Feng X, An P, Quan X, Wang H . MicroRNA-126 functions as a tumor suppressor in colorectal cancer cells by targeting CXCR4 via the AKT and ERK1/2 signaling pathways. Int J Oncol. 2013; 44(1):203-10. DOI: 10.3892/ijo.2013.2168. View

19.

Liu L, Li H, Li J, Zhong H, Zhang H, Chen J . miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem Biophys Res Commun. 2011; 416(1-2):31-8. DOI: 10.1016/j.bbrc.2011.10.117. View

20.

Li J, Ji Z, Qiao C, Qi Y, Shi W . Overexpression of ADAM9 Promotes Colon Cancer Cells Invasion. J Invest Surg. 2016; 26(3):127-133. DOI: 10.3109/08941939.2012.728682. View